Benzinga | Sep 16, 2021 02:01PM EDT

Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy

* Bristol Myers Squibb Co (NYSE:BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

* Data were presented at the European Society for Medical Oncology Virtual Congress 2021 (ESMO21).

* Related Link: Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting.

* The Phase 3 CheckMate-214 trial showed a five-year survival rate of 48% and 37% for those receiving sunitinib.

* After a median follow-up of 67.7 months, patients on the dual immunotherapy lived a median of 47 months versus 26.6 months for Pfizer Inc's (NYSE:PFE) targeted therapy Sutent (sunitinib).

* Opdivo plus Yervoy continued to show a higher ORR (39% vs. 32%) and complete response rate than sunitinib (12% vs. 3%).

* Also, more patients treated with the combination achieved complete responses and subsequently did not progress (9.6% vs. 2.4%).

* The safety profile of Opdivo plus Yervoy was manageable.

* Related: Bristol Myers Scores FDA Approval For Opdivo In Postsurgery Bladder Cancer.

* Price Action: BMY stock is down 1.66% at $60.97 during the market session on the last check Thursday.

* Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)